Venture Capital Vi, L.P.Ver... Net Worth

The estimated Net Worth of Venture Capital Vi, L.P.Ver... is at least $719 Тысяча dollars as of 3 March 2020. Venture Ver owns over 225,000 units of Passage Bio Inc stock worth over $718,681 and over the last 5 years Venture sold PASG stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Venture Ver PASG stock SEC Form 4 insiders trading

Venture has made over 1 trades of the Passage Bio Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Venture bought 225,000 units of PASG stock worth $4,050,000 on 3 March 2020.

The largest trade Venture's ever made was buying 225,000 units of Passage Bio Inc stock on 3 March 2020 worth over $4,050,000. On average, Venture trades about 225,000 units every 0 days since 2020. As of 3 March 2020 Venture still owns at least 933,352 units of Passage Bio Inc stock.

You can see the complete history of Venture Ver stock trades at the bottom of the page.

Insiders trading at Passage Bio Inc

Over the last 5 years, insiders at Passage Bio Inc have traded over $535,533 worth of Passage Bio Inc stock and bought 4,392,148 units worth $41,339,284 . The most active insiders traders include Liam Ratcliffe, Advisors Llc Orbi Med Capit... и Thomas Woiwode. On average, Passage Bio Inc executives and independent directors trade stock every 37 days with the average trade being worth of $92,858. The most recent stock trade was executed by Kathleen Borthwick on 10 February 2024, trading 4,000 units of PASG stock currently worth $3,080.

What does Passage Bio Inc do?

passage bio, inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (cns) diseases. the company develops pbgm01, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional glb1 gene encoding lysosomal acid beta-galactosidase (ãŸ-gal) for infantile gm1; pbft02, which utilizes an aav1 capsid to deliver to the brain a functional granulin, or grn, gene encoding progranulin for the treatment of ftd caused by a deficiency of progranulin; and pbkr03, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional galc gene encoding the hydrolytic enzyme galactosylceramidase, for infantile krabbe disease. it has a strategic research collaboration with the trustees of the university of pennsylvania's gene therapy program; and collaboration agreement, and a development services and clinical supply agreement with catalent maryland, inc. the company was fou

Complete history of Venture Ver stock trades at Passage Bio Inc

Passage Bio Inc executives and stock owners

Passage Bio Inc executives and other stock owners filed with the SEC include:

• Dr. Bruce A. Goldsmith M.B.A., Ph.D.,
  CEO, Pres & Director
• Dr. Maxine Gowen M.B.A., Ph.D.,
  Interim Exec. Chairwoman
• Desiree Luthman D.D.S.,
  Sr. VP of Global Regulatory Affairs
• Dr. Mark Forman M.D., Ph.D.,
  Chief Medical Officer
• Monika Tornsen,
  Chief Commercial Officer
• Gregory Fuest,
  VP of Global Commercial Strategy & Marketing
• Alexandros Fotopoulos MBA, MSc,
  Chief Technical Officer
• Monika Maria Tornsen,
  Chief Commercial Officer
• Dr. Eliseo Oreste Salinas M.D., M.Sc.,
  Chief R&D Officer
• Robin DeRogatis M.B.A.,
  Sr. VP HR
• Gwen Fisher M.B.A.,
  VP of Corp. Communications
• Edgar B. Cale Esq., J.D.,
  Gen. Counsel & Company Sec.
• Stuart M. Henderson,
  VP Investor Relations & Strategic Fin.
• Alexandros Fotopoulos MSc, MBA,
  Chief Technical Officer
• Simona King,
  CFO & Corp. Sec.
• Dr. James M. Wilson M.D., Ph.D.,
  Co-Founder & Chief Scientific Advisor
• Bruce A Goldsmith,
  CEO and President
• Life Sciences Ix, L.P.Fhmls...,
  
• Venture Capital Vi, L.P.Ver...,
  
• Advisors Llc Orbi Med Capit...,
  
• Eliseo Oreste Salinas,
  Chief Res. & Develop Officer
• Mark S Forman,
  CHIEF MEDICAL OFFICER
• Monika Maria Toernsen,
  Chief Commercial Officer
• Stephen P Squinto,
  Head of Research and Dev
• Jill M. Quigley,
  Chief Operating Officer
• Richard Steven Morris,
  Chief Financial Officer
• Gary Romano,
  Chief Medical Officer
• Patrick J Heron,
  Director
• Liam Ratcliffe,
  Director
• Thomas Woiwode,
  Director
• Tadataka Yamada,
  Director
• Edgar B. Cale,
  GC & CORPORATE SECRETARY
• Kathleen Borthwick,
  CFO
• Derrell Porter,
  
• Simona King,
  Chief Financial Officer
• Saqib Islam,
  
• Dolan Sondhi,
  
• Maxine Gowen,
  
• Sandip Kapadia,
  
• Athena Countouriotis,
  
• Michael E. Kamarck,
  Director
• William Chou,
  PRESIDENT AND CEO